The in vitro activity of HER-targeted agents across different HER2 mutations has been evaluated in preclinical NSCLC models, with both afatinib and neratinib exhibiting significantly increased efficacy toward the A775_G776insYVMA exon 20 insertion [61]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.